Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,722.81
(
0.35%
)
US TECH 100
24,148.80
(
0.56%
)
Dow Jones
47,075.93
(
0.28%
)
Brent Oil
100.15
(
1.88%
)
Bitcoin
73,931.31
(
-1.22%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dangerM post# 213668

Monday, 11/13/2017 5:35:59 PM

Monday, November 13, 2017 5:35:59 PM

Post# of 257251
MRTX tightens focus to Sitravatinib/KRAS programs—Glesatinib development discontinued:

https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-advancement-of-first-in-class-opportunities-with-sitravatinib-and-kras-inhibitor-programs-300554979.html

Sitravatinib is the drug that showed an ORR of 27% (3/11) when combined with Opdivo in NSCLC PD-1 failures (#msg-134629963).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now